3. Eli Lilly’s Elanco – Top 10 animal health companies

A cow and dog touching noses

Elanco logoEli Lilly’s Elanco ($LLY)
2015 Revenue: $3.18 billion
HQ: Greenfield, IN

Eli Lilly kicked off 2015 by closing a $5.4 billion acquisition of Novartis ($NVS) Animal Health, rocketing its Elanco division into the top 3 players in the veterinary products industry. The deal greatly expanded Elanco’s R&D and manufacturing footprint, and it gave Lilly a bigger presence in the market for drugs to treat companion animals. Mid-year rumors that Lilly might spin off Elanco briefly caused the company’s stock to soar, but once that speculation was quashed, investors returned to focusing on Lilly’s strong animal health assets, which include several vaccines for poultry and cattle, as well as parasiticides for pets. There have been some bumps in the road--Elanco’s U.S. sales dipped on decreased demand for food animal products, and the company had to sell a troubled manufacturing facility in California that it picked up in the Novartis deal--but the acquisition pushed the company’s overall animal health sales up 36% for the year.

Related Articles: 
Elanco debuts immune-boosting cow drug at USDA confab
Lilly quashes rumors of Elanco spinoff as stock soars
Lilly closes Novartis deal, creating second-largest animal health giant

3. Eli Lilly’s Elanco – Top 10 animal health companies

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…